A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

NCT04757363 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Esophagogastric Cancer
HER2-Negative

Interventions

DRUG: regorafenib
DRUG: nivolumab
DRUG: FOLFOX chemotherapy with oxaliplatin

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]